MedaRed is a biotechnology company focused on discovering and developing new therapeutics targeting fibrin. MedaRed is founded upon the pioneering work of Dr. Katerina Akassoglou, PhD, Senior Investigator at Gladstone Institutes and Professor of Neurology at the University of California, San Francisco. Dr. Akassoglou and colleagues discovered that fibrin, a blood-clotting factor, is implicated in the toxic inflammation that damages neurons in neurological diseases including Alzheimer's disease (AD) and multiple sclerosis (MS). MedaRed's key technology was invented by its co-founder Katerina Akassoglou, PhD, who discovered molecules that reduce neuroinflammation and the subsequent damage to neurons.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/09/19 | $6,500,000 | Seed |
Dementia Discovery Fund Dolby Family Ventures | undisclosed |
